EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²

Umut Yılmaz iD, Şükran Erdem Nurcan iD, Deniz Özmen iD, Ayşe Salihoğlu, Ahmet Emre Eşkazan, Şeniz Öngören, Zafer Başlar, Teoman Soysal iD, Muhlis Cem Ar, Tuğrul Elverdi

Annals of Transplantation · 2025

DOI: 10.12659/aot.947186 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Transplantation, 2025. Verfasst von Umut Yılmaz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Myeloma, Melphalan, Myeloablative Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMultiple MyelomaMelphalanMyeloablative AgonistsRetrospective StudiesTransplantation, AutologousTransplantation ConditioningDose-Response Relationship, DrugFollow-Up StudiesBortezomibProgression-Free SurvivalInduction ChemotherapyHumansMaleFemaleAdultMiddle AgedAgedTreatment Outcome

Substanzen

MelphalanMyeloablative AgonistsBortezomib

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

ORCID-Profile: Umut Yılmaz, Şükran Erdem Nurcan, Deniz Özmen, Teoman Soysal

Zitieren

APA

Yılmaz, U., Erdem Nurcan, Ş., Özmen, D., Salihoğlu, A., Eşkazan, A. E., Öngören, Ş., Başlar, Z., Soysal, T., Ar, M. C., & Elverdi, T. (2025). Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m². Annals of Transplantation. https://doi.org/10.12659/aot.947186

Vancouver

Yılmaz U, Erdem Nurcan Ş, Özmen D, Salihoğlu A, Eşkazan AE, Öngören Ş, et al. Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m². Annals of Transplantation. 2025. doi:10.12659/aot.947186

BibTeX
@article{Ylmaz2025,
  author = {Yılmaz, Umut and Erdem Nurcan, Şükran and Özmen, Deniz and Salihoğlu, Ayşe and Eşkazan, Ahmet Emre and Öngören, Şeniz and Başlar, Zafer and Soysal, Teoman and Ar, Muhlis Cem and Elverdi, Tuğrul},
  title = {Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²},
  journal = {Annals of Transplantation},
  year = {2025},
  doi = {10.12659/aot.947186}
}
Kostenlos starten →